ArticlePain research & management2026
Treatment of Trigeminal Zoster-Associated Pain With Burst and Tonic Trigeminal Ganglion Stimulation: A Retrospective Study.
Article in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment of Trigeminal Zoster-Associated Pain With Burst and Tonic Trigeminal Ganglion Stimulation: A Retrospective Study.Pain research & management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeEvidence regarding the efficacy of trigeminal ganglion stimulation for refractory trigeminal zoster-associated pain (TZAP) is limited. This study investigated the use of percutaneous trigeminal ganglion stimulation in a series of TZAP patients and evaluated the efficacy of burst trigeminal ganglion stimulation (bTGS) and tonic trigeminal ganglion stimulation (tTGS) modalities on pain relief. PATIENTS AND
methodsWe retrospectively reviewed all eligible TZAP patients who received temporary trigeminal ganglion stimulation in our department between January 2022 and August 2024. Spontaneous pain and mechanical allodynia intensity were assessed using the numeric rating scale (NRS) before treatment and at 1 week, the day of electrode removal, 1 month, 2 months, and 3 months post-treatment. Other symptoms, pain interference with sleep, and scores on the self-rating depression scale and self-rating anxiety scale were also recorded.
resultsAmong 31 patients, 16 received tTGS and 15 received bTGS. Compared with baseline, there was a statistically significant decrease in spontaneous pain NRS scores at 3 months (mean difference, 5.0; 95% CI, 4.2-5.8; p < 0.001). Similarly, the proportion of patients with mechanical allodynia NRS scores 3 or less increased significantly at 3 months (difference in proportions, 61.3%; 95% CI, 42.2%-80.4%; p < 0.001). In the tTGS group, the mean spontaneous pain NRS score decreased from 8.1 (95% CI, 7.5-8.8) at baseline to 3.2 (95% CI, 1.8-4.6) at 3 months (p < 0.001). In the bTGS group, the mean spontaneous pain NRS score decreased from 7.3 (95% CI, 6.6-8.1) at baseline to 2.3 (95% CI, 1.2-3.3, p < 0.001) at 3 months (p < 0.001). No serious adverse events occurred.
conclusionThis retrospective study suggests that trigeminal ganglion stimulation is a promising therapeutic option for patients with TZAP and that bTGS may serve as a feasible alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.